You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

APREPITANT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Aprepitant patents expire, and when can generic versions of Aprepitant launch?

Aprepitant is a drug marketed by Glenmark Pharms Sa, Sandoz, and Torrent. and is included in three NDAs.

The generic ingredient in APREPITANT is aprepitant. There are twenty-six drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the aprepitant profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Aprepitant

A generic version of APREPITANT was approved as aprepitant by SANDOZ on September 24th, 2012.

  Try a Trial

Drug patent expirations by year for APREPITANT
Drug Prices for APREPITANT

See drug prices for APREPITANT

Recent Clinical Trials for APREPITANT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 4
Guangxi Medical UniversityPhase 3
Hospital General TlahuacPhase 4

See all APREPITANT clinical trials

Paragraph IV (Patent) Challenges for APREPITANT
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
APONVIE Intravenous Emulsion aprepitant 32 mg/4.4 mL 216457 1 2023-11-07
CINVANTI Intravenous Emulsion aprepitant 130 mg/18 mL 209296 1 2022-04-29
EMEND for Oral Suspension aprepitant 125 mg/Kit 207865 1 2016-11-23
EMEND Capsule aprepitant 40 mg, 80 mg and 125 mg 021549 1 2008-11-03

US Patents and Regulatory Information for APREPITANT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glenmark Pharms Sa APREPITANT aprepitant CAPSULE;ORAL 207777-001 Oct 12, 2017 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Torrent APREPITANT aprepitant CAPSULE;ORAL 211835-001 Oct 21, 2020 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Sandoz APREPITANT aprepitant CAPSULE;ORAL 090999-001 Sep 24, 2012 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Torrent APREPITANT aprepitant CAPSULE;ORAL 211835-002 Oct 21, 2020 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Glenmark Pharms Sa APREPITANT aprepitant CAPSULE;ORAL 207777-002 Oct 12, 2017 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for APREPITANT

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Merck Sharp & Dohme B.V. Emend aprepitant EMEA/H/C/000527
Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.Emend is also available as 80 mg and 125 mg hard capsules for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12 (see separate Summary of Product Characteristics).Emend is also available as 165 mg hard capsules for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.Emend is also available as powder for oral suspension for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years.Emend 80 mg, 125 mg, 165 mg hard capsules and Emend powder for oral suspension are given as part of combination therapy.
Authorised no no no 2003-11-11
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.